FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885416375> ?p ?o ?g. }

• W2885416375 endingPage "428" @default.
• W2885416375 startingPage "418" @default.
• W2885416375 abstract "Aims/Introduction We investigated the safety and tolerability of empagliflozin (EMPA) in East Asian patients with type 2 diabetes. Materials and Methods Data were pooled from participants with type 2 diabetes evenly randomized to a placebo, EMPA 10 mg or EMPA 25 mg in 15 phase I–III trials. Adverse events (AEs) were analyzed in the subgroup of trial participants from East Asian countries/regions. Results In total, 709, 724 and 708 East Asian trial participants with type 2 diabetes received a placebo, EMPA 10 mg and EMPA 25 mg, respectively; total exposure was 953, 1,072, and 1,033 patient-years in these groups, respectively. The EMPA and placebo groups had similar incidences of severe AEs, serious AEs and AEs leading to discontinuation. Incidences of hypoglycemia differed according to anti-diabetes medication used at baseline. Higher rates of events consistent with genital infection were observed with EMPA (EMPA 1.5–1.7/100, placebo 0.2/100 patient-years). Rates of AEs consistent with volume depletion were comparable among treatment groups (0.8–1.4/100 patient-years), but in trial participants aged ≥65 years, the rate was greater with EMPA 25 mg (EMPA 25 mg 3.5/100, placebo 2.0/100 patient-years). Incidences of events consistent with urinary tract infection, thromboembolic events, renal events, hepatic AEs, diabetic ketoacidosis, fractures and lower limb amputation were similar between EMPA and the placebo. Conclusions In the present pooled analysis, EMPA was well tolerated in East Asian type 2 diabetes patients based on >2,100 patient-years’ exposure, consistent with results from the overall analysis population." @default.
• W2885416375 created "2018-08-22" @default.
• W2885416375 creator A5005670041 @default.
• W2885416375 creator A5006125844 @default.
• W2885416375 creator A5015002294 @default.
• W2885416375 creator A5018481785 @default.
• W2885416375 creator A5019886336 @default.
• W2885416375 creator A5026398619 @default.
• W2885416375 creator A5034574461 @default.
• W2885416375 creator A5052412166 @default.
• W2885416375 creator A5060236174 @default.
• W2885416375 creator A5065699667 @default.
• W2885416375 creator A5081052339 @default.
• W2885416375 creator A5081800565 @default.
• W2885416375 date "2018-09-20" @default.
• W2885416375 modified "2023-10-16" @default.
• W2885416375 title "Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials" @default.
• W2885416375 cites W1567871412 @default.
• W2885416375 cites W1682854201 @default.
• W2885416375 cites W1714643869 @default.
• W2885416375 cites W1799522345 @default.
• W2885416375 cites W1847388060 @default.
• W2885416375 cites W1899868128 @default.
• W2885416375 cites W1944521216 @default.
• W2885416375 cites W1946550634 @default.
• W2885416375 cites W1995006519 @default.
• W2885416375 cites W2002810160 @default.
• W2885416375 cites W2008687581 @default.
• W2885416375 cites W2051243940 @default.
• W2885416375 cites W2067448646 @default.
• W2885416375 cites W2076716357 @default.
• W2885416375 cites W2090979363 @default.
• W2885416375 cites W2101344933 @default.
• W2885416375 cites W2101374656 @default.
• W2885416375 cites W2117512154 @default.
• W2885416375 cites W2128219379 @default.
• W2885416375 cites W2133036275 @default.
• W2885416375 cites W2134455358 @default.
• W2885416375 cites W2137069992 @default.
• W2885416375 cites W2137107263 @default.
• W2885416375 cites W2138173919 @default.
• W2885416375 cites W2142065502 @default.
• W2885416375 cites W2146264128 @default.
• W2885416375 cites W2152413054 @default.
• W2885416375 cites W2165956693 @default.
• W2885416375 cites W2169669025 @default.
• W2885416375 cites W2171471305 @default.
• W2885416375 cites W2172193326 @default.
• W2885416375 cites W2180519544 @default.
• W2885416375 cites W2188229898 @default.
• W2885416375 cites W2202866687 @default.
• W2885416375 cites W2417253994 @default.
• W2885416375 cites W2424539745 @default.
• W2885416375 cites W2493381021 @default.
• W2885416375 cites W2524330917 @default.
• W2885416375 cites W2532116684 @default.
• W2885416375 cites W2561077285 @default.
• W2885416375 cites W2567447584 @default.
• W2885416375 cites W2574115541 @default.
• W2885416375 cites W2626446274 @default.
• W2885416375 cites W2653321410 @default.
• W2885416375 cites W2733849831 @default.
• W2885416375 cites W2737083386 @default.
• W2885416375 cites W2769721741 @default.
• W2885416375 cites W2788464339 @default.
• W2885416375 cites W2807917318 @default.
• W2885416375 cites W2808317629 @default.
• W2885416375 cites W2808615577 @default.
• W2885416375 cites W2885416375 @default.
• W2885416375 doi "https://doi.org/10.1111/jdi.12910" @default.
• W2885416375 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6400242" @default.
• W2885416375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30099847" @default.
• W2885416375 hasPublicationYear "2018" @default.
• W2885416375 type Work @default.
• W2885416375 sameAs 2885416375 @default.
• W2885416375 citedByCount "26" @default.
• W2885416375 countsByYear W28854163752019 @default.
• W2885416375 countsByYear W28854163752020 @default.
• W2885416375 countsByYear W28854163752021 @default.
• W2885416375 countsByYear W28854163752022 @default.
• W2885416375 countsByYear W28854163752023 @default.
• W2885416375 crossrefType "journal-article" @default.
• W2885416375 hasAuthorship W2885416375A5005670041 @default.
• W2885416375 hasAuthorship W2885416375A5006125844 @default.
• W2885416375 hasAuthorship W2885416375A5015002294 @default.
• W2885416375 hasAuthorship W2885416375A5018481785 @default.
• W2885416375 hasAuthorship W2885416375A5019886336 @default.
• W2885416375 hasAuthorship W2885416375A5026398619 @default.
• W2885416375 hasAuthorship W2885416375A5034574461 @default.
• W2885416375 hasAuthorship W2885416375A5052412166 @default.
• W2885416375 hasAuthorship W2885416375A5060236174 @default.
• W2885416375 hasAuthorship W2885416375A5065699667 @default.
• W2885416375 hasAuthorship W2885416375A5081052339 @default.
• W2885416375 hasAuthorship W2885416375A5081800565 @default.
• W2885416375 hasBestOaLocation W28854163751 @default.
• W2885416375 hasConcept C126322002 @default.
• W2885416375 hasConcept C134018914 @default.
• W2885416375 hasConcept C138411078 @default.

• next